Type I Collagen Matrix Plus Polyhexamethylene Biguanide Antimicrobial for VLUs

Dr Michael Sabolinski discusses the findings of a secondary analysis of patients with VLUs who participated in the RESPOND Registry. Read the original study here. 

TRANSCRIPT

Hi, my name is Mike Sabolinski, and I'm one of the co-authors of the article, “A Prospective Non-interventional Study of Type I Collagen Matrix Plus PHMB for the Treatment of Venous Leg Ulcers.” This is a secondary analysis of the RESPOND Registry, which looked at PCMP in a variety of cutaneous wounds.

The purpose of this secondary analysis was to describe the effects of PCMP in the subgroup of patients with venous leg ulcer. We conducted the study at 28 sites. It was prospective, noninterventional, and patients were followed for 32 weeks.

The important results of this study was that the cohort of PCMP-treated VLUs, and there were 67 of them, showed for us that there was a large mean baseline wound area of over 20 cm², and the duration of having those ulcers was approximately three months. Wound closure frequencies were reported as 33, 42, 45, 53, and 73% at weeks 8, 12 16, 24, and end of study, week 32, respectively. The median time to wound closure was 22 weeks, and the incidence of achieving both greater than 60% reduction in baseline area and depth were over 75% and 60%, respectively. Seventy-eight percent of the PCMP treated ulcers showed a reduction of greater than 75% in volume.

Our conclusion is that PCMP certainly appeared to be a valuable adjunct for treating venous leg ulcers.

We look forward to running additional comparative effectiveness assessments and encourage you to read the article. Thank you.